- Global Pharma News & Resources

Rise in the incidences of diabetes will boost the retinal biologics market, forecast to touch US$ 34,187.78 Million by 2025 at a CAGR of 6.3%.

Noida, Uttar Pradesh, India, February 17 2021 (Wiredrelease) Report Ocean Pvt Ltd –:The rapidly growing diabetes cases worldwide are the primary driver for the global retinal biologics market growth. Morbidity, mortality, and the economic burden associated with diabetes-related problems have been revealed as the primary public health concern globally. In addition, diabetic retinopathy is one of the leading reasons for vision loss cases around the world. Various reports on diabetic retinopathy have been estimated that the number of diabetic retinopathy suffering cases are 422 million in 2019 and may reach 629 million by 2045. Driven by these promising developments, the Global retinal biologics Market is estimated to see healthy growth, pegged at a CAGR of 6.3% during the forecast period 2020-2025.


Diabetic Retinopathy Shows Lucrative Opportunity in the Global Retinal Biologics Market

Diabetic retinopathy is a leading cause of vision-loss globally. According to the International Diabetes Federation, the devastating consequences of diabetes mellitus are set to continue due to the predicted increase in prevalence from 463 million in 2019 to 700 million in 2045. Among this diabetic population, the global prevalence of diabetic retinopathy (DR) and diabetic macular edema (DME) for 2019 was 27.0%. The lowest majority was in Europe at 20.6% and South East Asia at 12.5%, and highest in Africa at 33.8%, Middle East and North Africa 33.8%, and the Western Pacific region at 36.2%.

The most clinically significant risk factors for vision loss progression include the duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure effectively prevents vision loss due to DR. Hence, the rising prevalence of DR and the growing awareness and concern are expected to drive the segment growth over the forecast period.

Sector Introduction

The retina is the most sensitive part of the human eye. It is responsible for receiving and processing illuminations to convert into neural signals and to further share or send them to the brain cells for visual working. The retinal health disorders include diabetic retinopathy, age-related macular degeneration, macular edema, macular hole, infectious retinitis, retinal degeneration, retinoschisis, retinoblastoma, and uveitis, among others. There are numerous retinal disorder types, but most of them cause visual symptoms.

The global retinal biologics market is highly fragmented due to several players across developed and developing economies. Besides, the rising number of age-related macular degeneration and diabetic eye diseases are expected to create massive demand for the consumption of retinal biologics across the globe during the forecast period.

Segmentation Overview of the Global retinal biologics Market

The retinal biologics market is segmented based on drug class, disease indication, and distribution channel. These major market segments are further categorized into various sub-segments to study the market in detail.

By Drug Class Outlook

VEGF-A Antagonist TNF-a Inhibitor

By Disease Indication Outlook

Macular Degeneration Diabetic Retinopathy Uveitis Others

By Distribution Channel Outlook

Retail Pharmacies Hospital Pharmacies Specialty Ophthalmology Clinics

Key Players Insights

Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Amgen Inc., Oxurion NV, MeiraGTx Limited, Spark Therapeutics, Inc., AbbVie Inc., Regeneron Pharmaceuticals, Inc., and Novartis International AG, among others, are some major players included in the research study of the global retinal biologics market.

Research Report on the Global Retinal Biologics Market Include:

Economic Sectors and Share of Retinal Biologics
Global Retinal Biologics Market Size Forecast
Retinal Biologics Performance Index
Industry Structure by Segments
Growth Prospects
Healthcare Sector globally
Retinal Biologics Drivers
Regional Opportunities and Trends
Retinal Drugs and Biologics Market
Retinal Biologics Competitors Landscape
Emerging Technologies


This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 17-Feb-2021